share in the fast-growing US Novo Nordisk ® TRx share 60% 49.6% 40% US GLP-1 TRx market share Class growth ~30% 52.3% 44.4% 33.2% 20% 0% October 2020 ctoza ® NN GLP-1 dulaglutide 12.2% 6.9% October 2021
Download PDF file